At the January meeting of AICC’s Medical Committee, three Israeli medical device Israeli start-up companies presented to the members. The meeting was hosted by Eric Vayle at the Buckhead office of Jones Lang LaSalle Americas, a real estate and investment management services firm that assists clients (including Israeli companies) with US office locations.
CEO Uzi Eshel presented this Hod-Hasharon-based developer of a doctor’s office-based system (console & catheters) that thermally treats bladder cancer and Prostatitis. Elmedical’s proprietary innovative technologies, UniThermia and DuoThermia, covered by issued and pending patents, has unique advantages over current thermal-treatment devices for these diseases including FDA approved ones. FDA recently approved a thermo-chemotherapy drug / device combination for bladder cancer – Synergo – which opens US opportunities for FDA accelerated approval and strategic partnerships. Currently, Elmedical is focusing on bladder cancer and later will expand its activities in prostatitis. The company currently has the CE mark and Israeli approvals and is already selling in Europe and Israel.
General Manager Yaron Aizenbud presented this start-up located in the Misgav Venture Accelerator that has developed an innovative orthopedic and spinal anchoring system that has many advantages over the regular pedicle screw. They include enhanced implant stability, resistance to loosening, better load distribution, better anchoring for osteoporotic bones, and a less invasive surgical approach enabled by the curved element design.
CEO Yoram Izhaki presented this Rehovot-based start-up that is commercializing the A-Shield, a discovery of its founders that is a new method for killing bacteria and fungi without releasing any chemical into the surrounding environment or using any energy source. It is being applied as a thin coating layer to a variety of products, providing them with long-lasting antimicrobial properties. The initial application is for a urology catheter, and the initial test results have proven to be dramatic. They expect to have an industrial prototype of the antimicrobial urinary catheter in four to six months, and then begin FDA filing. Recent change in Medicare and Medicaid payment for CAUTI (catheter associated urinary tract infection), may cause increased interest in this type of product.